95 results on '"Shah, Svati H."'
Search Results
2. Molecular Aspects of Lifestyle and Environmental Effects in Patients With Diabetes: JACC Focus Seminar.
- Author
-
Nayor, Matthew, Shah, Svati H., Murthy, Venkatesh, and Shah, Ravi V.
- Subjects
- *
PEOPLE with diabetes , *BIOLOGICAL systems , *METABOLIC disorders , *DIABETES complications , *CARDIOVASCULAR system , *DIAGNOSIS of diabetes , *TREATMENT of diabetes , *LIFESTYLES , *ECOLOGY , *DIABETES , *PHENOTYPES - Abstract
Diabetes is characterized as an integrated condition of dysregulated metabolism across multiple tissues, with well-established consequences on the cardiovascular system. Recent advances in precision phenotyping in biofluids and tissues in large human observational and interventional studies have afforded a unique opportunity to translate seminal findings in models and cellular systems to patients at risk for diabetes and its complications. Specifically, techniques to assay metabolites, proteins, and transcripts, alongside more recent assessment of the gut microbiome, underscore the complexity of diabetes in patients, suggesting avenues for precision phenotyping of risk, response to intervention, and potentially novel therapies. In addition, the influence of external factors and inputs (eg, activity, diet, medical therapies) on each domain of molecular characterization has gained prominence toward better understanding their role in prevention. Here, the authors provide a broad overview of the role of several of these molecular domains in human translational investigation in diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Cardiovascular Burden of the V142I Transthyretin Variant.
- Author
-
Selvaraj, Senthil, Claggett, Brian, Shah, Svati H., Mentz, Robert J., Khouri, Michel G., Manichaikul, Ani W., Khan, Sadiya S., Rich, Stephen S., Mosley, Thomas H., Levitan, Emily B., Arora, Pankaj, Goyal, Parag, Haring, Bernhard, Eaton, Charles B., Cheng, Richard K., Wells, Gretchen L., Manson, JoAnn E., Fontana, Marianna, and Solomon, Scott D.
- Subjects
- *
HEART failure , *TRANSTHYRETIN , *NATURAL history , *BLACK people , *RACE , *DISEASE vectors - Abstract
Key Points: Question: What is the natural history and cardiovascular burden of the V142I variant of the transthyretin (TTR) gene among US Black carriers across mid to late life? Findings: Across 4 cohort studies, carriers (754/23 338) faced a substantially increased risk for heart failure (by age 63 years) and death (by age 72 years), similarly in men and women, which was estimated to contribute to approximately 1 million years of life lost among US Black individuals aged ≥50 years. Meaning: These data show the large, age-dependent burden of V142I, which may guide discussions regarding the initiation and results of genetic screening, provide clinicians with risk estimates to share with patients, and inform strategies for early targeted therapy. Importance: Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin (TTR) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant clinical outcomes and estimating population burden of disease are important given established and emerging targeted treatments. Objectives: To better define the natural history of disease in carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population. Design, Setting, and Participants: A total of 23 338 self-reported Black participants initially free from HF were included in 4 large observational studies across the US (mean [SD], 15.5 [8.2] years of follow-up). Data analysis was performed between May 2023 and February 2024. Exposure: V142I carrier status (n = 754, 3.2%). Main Outcomes and Measures: Hospitalizations for HF (including subtypes of reduced and preserved ejection fraction) and all-cause mortality. Outcomes were analyzed by generating 10-year hazard ratios for each age between 50 and 90 years. Using actuarial methods, mean survival by carrier status was estimated and applied to the 2022 US population using US Census data. Results: Among the 23 338 participants, the mean (SD) age at baseline was 62 (9) years and 76.7% were women. Ten-year carrier risk increased for HF hospitalization by age 63 years, predominantly driven by HF with reduced ejection fraction, and 10-year all-cause mortality risk increased by age 72 years. Only age (but not sex or other select variables) modified risk with the variant, with estimated reductions in longevity ranging from 1.9 years (95% CI, 0.6-3.1) at age 50 to 2.8 years (95% CI, 2.0-3.6) at age 81. Based on these data, 435 851 estimated US Black carriers between ages 50 and 95 years are projected to cumulatively lose 957 505 years of life (95% CI, 534 475-1 380 535) due to the variant. Conclusions and Relevance: Among self-reported Black individuals, male and female V142I carriers faced similar and substantial risk for HF hospitalization, predominantly with reduced ejection fraction, and death, with steep age-dependent penetrance. Delineating the individual contributions of, and complex interplay among, the V142I variant, ancestry, the social construct of race, and biological or social determinants of health to cardiovascular disease merits further investigation. This study used data on Black participants in 4 large observational studies to better define the natural history of disease in V142I variant carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Rare Things Being Common: Implications for Common Genetic Variants in Rare Diseases Like Long-QT Syndrome.
- Author
-
Landstrom, Andrew P. and Shah, Svati H.
- Subjects
- *
RARE diseases , *BRUGADA syndrome , *INDUCED pluripotent stem cells , *CORONARY disease , *TREADMILL exercise tests , *LONG QT syndrome diagnosis , *GENETICS , *LONG QT syndrome , *SYMPTOMS - Abstract
In this issue, in the largest and most comprehensive such study in LQTS, Lahrouchi et al[3] pool 1656 LQTS cases, finding that common variants are associated with LQTS and may be a distinct genetic subtype of LQTS. These interesting results suggest that a significant proportion of LQTS disease burden is explained by common variation, and that a higher burden of common QT interval-associated variants increases risk of overt LQTS in genotype-negative patients. Last, the authors perform a discovery GWAS comparing the 1656 LQTS cases with 9890 non-LQTS controls, identifying common variation in the I NOS1AP, KCNQ1 i , and I KLF12 i genes as associated with LQTS. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
5. Opportunities for the Cardiovascular Community in the Precision Medicine Initiative.
- Author
-
Shah, Svati H., Arnett, Donna, Houser, Steven R., Ginsburg, Geoffrey S., MacRae, Calum, Mital, Seema, Loscalzo, Joseph, and Hall, Jennifer L.
- Subjects
- *
CARDIOVASCULAR diseases , *GENETICS , *MEDICINE , *HUMAN genome , *HEALTH outcome assessment , *CARDIOLOGY , *DRUG therapy , *HEALTH planning , *INTERPROFESSIONAL relations , *LONGITUDINAL method , *HEALTH policy , *PATENTS , *TUMORS , *DATA mining , *EVIDENCE-based medicine , *GOVERNMENT programs - Abstract
The Precision Medicine Initiative recently announced by President Barack Obama seeks to move the field of precision medicine more rapidly into clinical care. Precision medicine revolves around the concept of integrating individual-level data including genomics, biomarkers, lifestyle and other environmental factors, wearable device physiological data, and information from electronic health records to ultimately provide better clinical care to individual patients. The Precision Medicine Initiative as currently structured will primarily fund efforts in cancer genomics with longer-term goals of advancing precision medicine to all areas of health, and will be supported through creation of a 1 million person cohort study across the United States. This focused effort on precision medicine provides scientists, clinicians, and patients within the cardiovascular community an opportunity to work together boldly to advance clinical care; the community needs to be aware and engaged in the process as it progresses. This article provides a framework for potential involvement of the cardiovascular community in the Precision Medicine Initiative, while highlighting significant challenges for its successful implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Integrative Omics: Harnessing the Proteome to Maximize the Potential of the Genome.
- Author
-
McGarrah, Robert W. and Shah, Svati H.
- Subjects
- *
CARDIOVASCULAR diseases , *GENOMES , *NUCLEOTIDE sequencing , *PROTEOMICS , *MASS spectrometry , *GENOMICS - Abstract
The article offers information on genetics of cardiovascular disease (CVD) through genome-wide association studies and whole exome/ genome sequencing. Topics discusses include understanding of CVD genetics, integrating genome-wide and exome array genetic data with proteomic data, emerging DNA-aptamer immunoaffinity technology and evaluation of various proteins that provide less complex analytics for protein identification and annotation required by unbiased mass spectrometry based proteomics.
- Published
- 2018
- Full Text
- View/download PDF
7. Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular Diseases Form and Function.
- Author
-
Shah, Svati H., Kraus, William E., and Newgard, Christopher B.
- Subjects
- *
CARDIOVASCULAR diseases , *LIPIDS , *CHOLESTEROL , *TRIGLYCERIDES , *METABOLITES - Abstract
The article presents information on the identification of the mechanisms related to cardiovascular diseases (CVDs).The relationship between CVD and certain circulating lipids like cholesterol and triglycerides has been recognized. Metabolite signatures that enhance risk prediction models can be identified.
- Published
- 2012
- Full Text
- View/download PDF
8. Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.
- Author
-
Voora, Deepak and Shah, Svati H.
- Subjects
- *
STATINS (Cardiovascular agents) , *CARDIOVASCULAR disease prevention , *DRUG development , *DRUG efficacy , *LOW density lipoproteins , *CLINICAL trials - Published
- 2016
- Full Text
- View/download PDF
9. The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
- Author
-
Voora, Deepak, Shah, Svati H., Spasojevic, Ivan, Ali, Shazia, Reed, Carol R., Salisbury, Benjamin A., and Ginsburg, Geoffrey S.
- Subjects
- *
STATINS (Cardiovascular agents) , *DRUG side effects , *PHARMACOGENOMICS , *CLINICAL trials , *GENETIC polymorphisms , *CYTOCHROMES , *LOW density lipoproteins , *GENE frequency - Abstract
Objectives: We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. Background: Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation. Methods: The STRENGTH (Statin Response Examined by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety. Subjects (n = 509) were randomized to atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg followed by 80 mg, 80 mg, and 40 mg, respectively. We defined a composite adverse event (CAE) as discontinuation for any side effect, myalgia, or CK >3× upper limit of normal during follow-up. We sequenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for association with the CAE. Results: The CAE occurred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations). Sex was associated with CAE (percent female in CAE vs. no CAE groups, 66% vs. 50%, p < 0.01). SLCO1B1*5 was associated with CAE (percent with ≥1 allele in CAE vs. no CAE groups, 37% vs. 25%, p = 0.03) and those with CAE with no significant CK elevation (p ≤ 0.03). Furthermore, there was evidence for a gene-dose effect (percent with CAE in those with 0, 1, or 2 alleles: 19%, 27%, and 50%, trend p = 0.01). Finally, the CAE risk appeared to be greatest in those carriers assigned to simvastatin. Conclusions: SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand the results of a recent genome-wide association study of statin myopathy with CK >3× normal to milder, statin-induced, muscle side effects. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
10. Relationships Between Circulating Metabolic Intermediates and Insulin Action in Overweight to Obese, Inactive Men and Women.
- Author
-
Huffman, Kim M., Shah, Svati H., Stevens, Robert D., Bain, James R., Muehlbauer, Michael, Slentz, Cris A., Tanner, Charles J., Kuchibhatla, Maragatha, Houmard, Joseph A., Newgard, Christopher B., and Kraus, William E.
- Subjects
- *
INSULIN resistance , *OBESITY , *OVERWEIGHT persons , *GLUCOSE tolerance tests , *METABOLITES , *AMINO acids , *FATTY acids , *MASS spectrometry - Abstract
OBJECTIVE -- To determine whether circulating metabolic intermediates are related to insulin resistance and β-cell dysfunction in individuals at risk for type 2 diabetes. RESEARCH DESIGN AND METHODS--In 73 sedentary, overweight to obese, dyslipidemic individuals, insulin action was derived from a frequently sampled intravenous glucose tolerance test. Plasma concentrations of 75 amino acids, acylcarnitines, free fatty acids, and conventional metabolites were measured with a targeted, mass spectrometry-based platform. Principal components analysis followed by backward stepwise linear regression was used to explore relationships between measures of insulin action and metabolic intermediates. RESULTS -- The 75 metabolic intermediates clustered into 19 factors comprising biologically related intermediates. A factor containing large neutral amino acids was inversely related to insulin sensitivity (S[sub I]) (R² = 0.26). A factor containing fatty acids was inversely related to the acute insulin response to glucose (R² = 0.12). Both of these factors, age, and a factor containing medium-chain acylcarnitines and glucose were inversely and independently related to the disposition index (DI) (R² = 0.39). Sex differences were found for metabolic predictors of S[sub I] and DI. CONCLUSIONS -- In addition to the well-recognized risks for insulin resistance, elevated concentrations of large, neutral amino acids were independently associated with insulin resistance. Fatty acids were inversely related to the pancreatic response to glucose. Both large neutral amino acids and fatty acids were related to an appropriate pancreatic response, suggesting that these metabolic intermediates might play a role in the progression to type 2 diabetes, one by contributing to insulin resistance and the other to pancreatic failure. These intermediates might exert sex-specific effects on insulin action. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis.
- Author
-
Crosslin, David R., Shah, Svati H., Nelson, Sarah C., Haynes, Carol S., Connelly, Jessica J., Gadson, Shera, Goldschmidt-Clermont, Pascal J., Vance, Jeffery M., Rose, Jason, Granger, Chris B., Seo, David, Gregory, Simon G., Kraus, William E., and Hauser, Elizabeth R.
- Subjects
- *
LEUKOTRIENES , *ATHEROSCLEROSIS , *HUMAN genetics , *CARDIOVASCULAR diseases , *CORONARY arteries , *NUCLEIC acids , *MOLECULAR genetics - Abstract
Leukotrienes are arachidonic acid derivatives long known for their inflammatory properties and their involvement with a number of human diseases, most particularly asthma. Recently, leukotriene-based inflammation has also been shown to play an important role in atherosclerosis: ALOX5AP and LTA4H, both genes in the leukotriene biosynthesis pathway, have individually been shown to be associated with various cardiovascular disease (CVD) phenotypes. To assess the role of the leukotriene pathway in CVD pathogenesis, we performed genetic association studies of ALOX5AP and LTA4H in a family based study of early onset coronary artery disease (EOCAD) (GENECARD, 1,101 families) and in a non-familial dataset of EOCAD (CATHGEN, 656 cases and 405 controls). We found weak to moderate association between single nucleotide polymorphisms (SNPs) in ALOX5AP and LTA4H with EOCAD. The previously reported four-SNP haplotype (HapA) in ALOX5AP showed association with EOCAD in CATHGEN ( P = 0.02), while controlling for age, race and CVD risk factors. HapK, the previously reported ten-SNP haplotype in LTA4H was associated with EOCAD in CATHGEN ( P = 0.04). Another previously reported four-SNP haplotype in ALOX5AP (HapB) was not significant in our sample ( P = 0.39). The overall lack of (or weak) association of single SNPs as compared with the haplotype results demonstrates the need for analyzing multiple SNPs within each gene in such studies. Interestingly, we detected an association of SNPs in ALOX5 ( P < 0.05), the target of ALOX5AP, with CVD. Using a pathway-based approach, we also detected statistical evidence for interactions among ALOX5, ALOX5AP and LTA4H using RNA expression data from a collection of freshly harvested human aortas with varying degrees of atherosclerosis. The GENECARD families did not demonstrate evidence for linkage or association with ALOX5, ALOX5AP or LTA4H. Our results support a modest role for the leukotriene pathway in atherosclerosis pathogenesis, reveal important genomic interactions within the pathway, and suggest the importance of using pathway-based modeling for evaluating the genomics of atherosclerosis susceptibility. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis.
- Author
-
Shah, Svati H., Freedman, Neil J., Lisheng Zhang, Crosslin, David R., Stone, David H., Haynes, Carol, Johnson, Jessica, Nelson, Sarah, Liyong Wang, Connelly, Jessica J., Muehlbauer, Michael, Ginsburg, Geoffrey S., Crossman, David C., Jones, Christopher J. H., Vance, Jeffery, Sketch Jr., Michael H., Granger, Christopher B., Newgard, Christopher B., Gregory, Simon G., and Goldschmidt-Clermont, Pascal J.
- Subjects
- *
NEUROPEPTIDE Y , *HEART blood-vessels , *CORONARY arteries , *GENETIC polymorphisms , *GENOMICS , *ATHEROSCLEROSIS , *DISEASES - Abstract
Neuropeptide Y (NPY) is a strong candidate gene for coronary artery disease (CAD). We have previously identified genetic linkage to familial CAD in the genomic region of NPY. We performed follow-up genetic, biostatistical, and functional analysis of NPY in early-onset CAD. In familial CAD (GENECARD, N = 420 families), we found increased microsatellite linkage to chromosome 7p14 (OSA LOD = 4.2, p = 0.004) in 97 earliest age-of-onset families. Tagged NPY SNPs demonstrated linkage to CAD of a 6-SNP block (LOD = 1.58-2.72), family-based association of this block with CAD (p = 0.02), and stronger linkage to CAD in the earliest age-of-onset families. Association of this 6-SNP block with CAD was validated in: (a) 556 non-familial early-onset CAD cases and 256 controls (OR 1.46-1.65, p = 0.01-0.05), showing stronger association in youngest cases (OR 1.84-2.20, p = 0.0004-0.09); and (b) GENECARD probands versus non-familial controls (OR 1.79-2.06, p = 0.003-0.02). A promoter SNP (rs16147) within this 6-SNP block was associated with higher plasma NPY levels (p = 0.04). To assess a causal role of NPY in atherosclerosis, we applied the NPY1-receptor-antagonist BIBP-3226 adventitially to endothelium-denuded carotid arteries of apolipoprotein E-deficient mice; treatment reduced atherosclerotic neointimal area by 50% (p = 0.03). Thus, NPY variants associate with atherosclerosis in two independent datasets (with strong age-of-onset effects) and show allele-specific expression with NPY levels, while NPY receptor antagonism reduces atherosclerosis in mice. We conclude that NPY contributes to atherosclerosis pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
13. Inverse Association of General Joint Hypermobility With Hand and Knee Osteoarthritis and Serum Cartilage Oligomeric Matrix Protein Levels.
- Author
-
Hsiang-Cheng Chen, Shah, Svati H., Yi-Ju Li, Stabler, Thomas V., Jordan, Joanne M., and Byers Kraus, Virginia
- Subjects
- *
JOINT hypermobility , *OSTEOARTHRITIS , *EXTRACELLULAR matrix proteins , *PATIENTS , *GENETICS - Abstract
The article discusses a study which tested the hypothesis that cartilage oligomeric matrix protein levels are associated with hypermobility in patients with osteoarthritis (OA). The Carolinas Region Interaction of Aging Genes and Environment and a subset of the Genetics of Generalized Osteoarthritis are cohorts which are available for analysis. The results indicate that there is an inverse relationship between hypermobility and hand and knee OA.
- Published
- 2008
- Full Text
- View/download PDF
14. ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention
- Author
-
Shah, Svati H., Hauser, Elizabeth R., Crosslin, David, Wang, Liyong, Haynes, Carol, Connelly, Jessica, Nelson, Sarah, Johnson, Jessica, Gadson, Shera, Nelson, Charlotte L., Seo, David, Gregory, Simon, Kraus, William E., Granger, Christopher B., Goldschmidt-Clermont, Pascal, and Newby, L. Kristin
- Subjects
- *
BLOOD coagulation , *CARDIOVASCULAR diseases , *SURGICAL stents , *THROMBOSIS - Abstract
Abstract: Background: Use of drug-eluting stents (DES) has reduced in-stent restenosis after percutaneous coronary intervention (PCI); however, DES are associated with late stent thrombosis. There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis. Methods: We identified 46 consecutive cases that had undergone PCI with bare-metal stents who subsequently developed symptomatic in-stent restenosis of the target lesion (≥75% luminal narrowing) within 6 months. Forty-six age-, race-, vessel-diameter- and sex-matched controls without in-stent restenosis after PCI with bare-metal stent were also identified. Single-nucleotide polymorphisms (SNPs, N =82) from 39 candidate atherosclerosis genes were genotyped. Multivariable logistic regression models were used to test for association. Results: Five SNPs were associated with in-stent restenosis. Three ALOX5AP SNPs were most strongly associated, two with increased risk (OR 3.74, p =0.01; OR 3.46, p =0.02), and the third with decreased risk of in-stent restenosis (OR 0.09, p =0.004). Two ALOX5AP haplotypes were associated with in-stent restenosis (HapB: OR 3.13, p =0.03); and a haplotype similar to HapA: OR 0.14, p =0.0009). Conclusions: ALOX5AP, a gene within the inflammatory leukotriene pathway linked to and associated with coronary atherosclerosis, is also associated with in-stent restenosis. Genotyping these variants may help identify those at risk for in-stent restenosis who would benefit most from use of DES. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
15. Genetic and functional association of FAM5C with myocardial infarction.
- Author
-
Connelly, Jessica J., Shah, Svati H., Doss, Jennifer F., Gadson, Shera, Nelson, Sarah, Crosslin, David R., Hale, A. Brent, Xuemei Lou, Ty Wang, Haynes, Carol, Seo, David, Crossman, David C., Mooser, Vincent, Granger, Christopher B., Jones, Christopher J. H., Kraus, William E., Hauser, Elizabeth R., and Gregory, Simon G.
- Subjects
- *
GENETIC polymorphisms , *MYOCARDIAL infarction , *CHROMOSOMES , *CORONARY disease , *GENETICS - Abstract
Background: We previously identified a 40 Mb region of linkage on chromosome 1q in our early onset coronary artery disease (CAD) genome-wide linkage scan (GENECARD) with modest evidence for linkage (n = 420, LOD 0.95). When the data are stratified by acute coronary syndrome (ACS), this modest maximum in the overall group became a well-defined LOD peak (maximum LOD of 2.17, D1S1589/D1S518). This peak overlaps a recently identified inflammatory biomarker (MCP-1) linkage region from the Framingham Heart Study (maximum LOD of 4.27, D1S1589) and a region of linkage to metabolic syndrome from the IRAS study (maximum LOD of 2.59, D1S1589/D1S518). The overlap of genetic screens in independent data sets provides evidence for the existence of a gene or genes for CAD in this region. Methods: A peak-wide association screen (457 SNPs) was conducted of a region 1 LOD score down from the peak marker (168-198 Mb) in a linkage peak for acute coronary syndrome (ACS) on chromosome 1, within a family-based early onset coronary artery disease (CAD) sample (GENECARD). Results: Polymorphisms were identified within the 'family with sequence similarity 5, member C' gene (FAM5C) that show genetic linkage to and are associated with myocardial infarction (MI) in GENECARD. The association was confirmed in an independent CAD case-control sample (CATHGEN) and strong association with MI was identified with single nucleotide polymorphisms (SNPs) in the 3' end of FAM5C. FAM5C genotypes were also correlated with expression of the gene in human aorta. Expression levels of FAM5C decreased with increasing passage of proliferating aortic smooth muscle cells (SMC) suggesting a role for this molecule in smooth muscle cell proliferation and senescence. Conclusion: These data implicate FAM5C alleles in the risk of myocardial infarction and suggest further functional studies of FAM5C are required to identify the gene's contribution to atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Biomarker Bonanza? ⁎ [⁎] Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- Author
-
Califf, Robert M., Shah, Svati H., and Newby, L. Kristin
- Published
- 2010
- Full Text
- View/download PDF
17. Taking Cardiovascular Genetic Association Studies to the Next Level
- Author
-
Ginsburg, Geoffrey S., Shah, Svati H., and McCarthy, Jeanette J.
- Subjects
- *
DNA , *GENES , *C-reactive protein , *MEDICAL care - Abstract
Genetic information is beginning to have a direct impact on patient care and it is important that cardiologists appreciate the value and approaches to associating genetic variation and health outcomes. Genetic associations should be based on compelling genetic and biological hypotheses and should be statistically sound so as to reduce the possibility of “false discovery” in the setting of testing multiple hypotheses. Study designs should clearly define cases and controls and measurement of phenotypes. Finally, findings should be replicated in at least 1 independent cohort. Consideration of these principles should provide insight into disease biology based on genetic findings and encourage their meaningful adoption into clinical practice. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. Metabolomic profiling during ex situ normothermic perfusion before heart transplantation defines patterns of substrate utilization and correlates with markers of allograft injury.
- Author
-
Truby, Lauren K., Kwee, Lydia Coulter, Bowles, Dawn E., Casalinova, Sarah, Ilkayeva, Olga, Muehlbauer, Michael J., Huebner, Janet L., Holley, Christopher L., DeVore, Adam D., Patel, Chetan B., Kang, Lillian, Pla, Michelle Mendiola, Gross, Ryan, McGarrah, Robert W., Schroder, Jacob N., Milano, Carmelo A., and Shah, Svati H.
- Subjects
- *
HEART transplantation , *FREE fatty acids , *METABOLOMICS , *PERFUSION , *HOMOGRAFTS - Abstract
Cardiac metabolism is altered in heart failure and ischemia-reperfusion injury states. We hypothesized that metabolomic profiling during ex situ normothermic perfusion before heart transplantation (HT) would lend insight into myocardial substrate utilization and report on subclinical and clinical allograft dysfunction risk. Metabolomic profiling was performed on serial samples of ex situ normothermic perfusate assaying biomarkers of myocardial injury in lactate and cardiac troponin I (TnI) as well as metabolites (66 acylcarnitines, 15 amino acids, nonesterified fatty acids [NEFA], ketones, and 3-hydroxybutyrate). We tested for change over time in injury biomarkers and metabolites, along with differential changes by recovery strategy (donation after circulatory death [DCD] vs donation after brain death [DBD]). We examined associations between metabolites, injury biomarkers, and primary graft dysfunction (PGD). Analyses were performed using linear mixed models adjusted for recovery strategy, assay batch, donor-predicted heart mass, and time. A total of 176 samples from 92 ex situ perfusion runs were taken from donors with a mean age of 35 (standard deviation 11.3) years and a median total ex situ perfusion time of 234 (interquartile range 84) minutes. Lactate trends over time differed significantly by recovery strategy, while TnI increased during ex situ perfusion regardless of DCD vs DBD status. We found fuel substrates were rapidly depleted during ex situ perfusion, most notably the branched-chain amino acids leucine/isoleucine, as well as ketones, 3-hydroxybutyrate, and NEFA (least squares [LS] mean difference from the first to last time point −1.7 to −4.5, false discovery rate q < 0.001). Several long-chain acylcarnitines (LCAC), including C16, C18, C18:1, C18:2, C18:3, C20:3, and C20:4, increased during the perfusion run (LS mean difference 0.42-0.67, q < 0.001). Many LCACs were strongly associated with lactate and TnI. The change over time of many LCACs was significantly different for DCD vs DBD, suggesting differential trends in fuel substrate utilization by ischemic injury pattern. Changes in leucine/isoleucine, arginine, C12:1-OH/C10:1-DC, and C16-OH/C14-DC were associated with increased odds of moderate-severe PGD. Neither end-of-run nor change in lactate or TnI was associated with PGD. Metabolomic profiling of ex situ normothermic perfusion solution reveals a pattern of fuel substrate utilization that correlates with subclinical and clinical allograft dysfunction. This study highlights a potential role for interventions focused on fuel substrate modification in allograft conditioning during ex situ perfusion to improve allograft outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association.
- Author
-
Zaha, Vlad G. Chair, Hayek, Salim S. Vice Chair, Alexander, Kevin M., Beckie, Theresa M. FAHA, Hundley, W. Gregory FAHA, Kondapalli, Lavanya, Ky, Bonnie, Leger, Kasey J., Meijers, Wouter C., Moslehi, Javid J., Shah, Svati H. MHS, FAHA, Zaha, Vlad G, Hayek, Salim S, Beckie, Theresa M, Hundley, W Gregory, and Shah, Svati H
- Subjects
- *
TUMOR treatment , *RESEARCH funding - Abstract
Improving cancer survival represents the most significant effect of precision medicine and personalized molecular and immunologic therapeutics. Cardiovascular health becomes henceforth a key determinant for the direction of overall outcomes after cancer. Comprehensive tissue diagnostic studies undoubtedly have been and continue to be at the core of the fight against cancer. Will a systemic approach integrating circulating blood-derived biomarkers, multimodality imaging technologies, strategic panomics, and real-time streams of digitized physiological data overcome the elusive cardiovascular tissue diagnosis in cardio-oncology? How can such a systemic approach be personalized for application in day-to-day clinical work, with diverse patient populations, cancer diagnoses, and therapies? To address such questions, this scientific statement approaches a broad definition of the biomarker concept. It summarizes the current literature on the utilization of a multitude of established cardiovascular biomarkers at the intersection with cancer. It identifies limitations and gaps of knowledge in the application of biomarkers to stratify the cardiovascular risk before cancer treatment, monitor cardiovascular health during cancer therapy, and detect latent cardiovascular damage in cancer survivors. Last, it highlights areas in biomarker discovery, validation, and clinical application for concerted efforts from funding agencies, scientists, and clinicians at the cardio-oncology nexus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Genetic cardiomyopathies and clinical implications in heart transplant recipients: An opportunity for missed diagnoses.
- Author
-
Coniglio, Amanda C., Amos, Kaitlyn, and Shah, Svati H.
- Subjects
- *
HEART transplant recipients , *DIAGNOSTIC errors , *CARDIOMYOPATHIES , *HEART transplantation - Published
- 2022
- Full Text
- View/download PDF
21. Abstract 16946: Proteomics Identifies Inflammatory, Lipid, and Cell Proliferative Pathways in Diastolic Dysfunction in HIV: A CHART Substudy.
- Author
-
Shah, Svati H, Kwee, Lydia, McNulty, Steven, Hsue, Priscilla, Desvigne-Nickens, Patrice, Shah, Sanjiv J, Hernandez, Adrian F, Braunwald, Eugene, and Butler, Javed
- Subjects
- *
HEART failure , *PROTEOMICS , *TUMOR necrosis factor receptors , *TRANSFORMING growth factors , *CARRIER proteins , *FALSE discovery rate - Abstract
Background: Anti-retrovirals have shifted the epidemiology of heart failure in HIV from one of systolic dysfunction to that of diastolic dysfunction (DD), but the underlying mechanisms are incompletely understood. We hypothesized that a proteomics analysis could identify novel biomarkers of DD in HIV. Methods: The NIH-funded Characterizing Heart Function on Anti-Retroviral Therapy (CHART) study enrolled HIV-infected individuals through the Heart Failure Network (HFN) with the goal of identifying clinical, imaging, and molecular markers of DD in HIV. Using the Olink platform (proximity extension assay technology), we profiled 977 proteins in frozen plasma samples from the 195 individuals enrolled in CHART. Logistic regression was used to compare protein levels between DD cases (N=94) and controls without DD (N=101). Results: We observed differences in many proteins between DD+ and DD- including inflammation (EDA2R, TNF-R1, TNFRSF19, VSIG4), lipid metabolism (leptin, FABP4, CLMP, PON3, PLIN1), cell proliferation and cell-cell adhesion (IGFBP6, TGFBR2, NOV, INHBC), and extracellular matrix (COL18A1, PRELP, HSPG2, COL1A1) proteins (p= 1.4x10-3 – 1.2x10-4). Of these, eight met false discovery rate (FDR) adjustment (EDA2R [tumor necrosis factor receptor superfamily member], leptin, FABP4 [fatty acid binding protein 4], CLMP [cell-cell adhesion, adipocyte differentiation], IGFBP6 [IGF binding protein involved in cell proliferation], TGFBR2 [transforming growth factor binding receptor 2], NOV [cell proliferation and adhesion], INHBC [member of TGF-β superfamily involved in cell development], and adrenomedullin, all FDR p<0.05). Adjustment for BMI, SBP, age, creatinine attenuated results (nominal p=0.24 – 1.3x10-3). Pathway analysis identified extracellular space, TNF activated receptor activity, cytokine-cytokine receptor interaction, collagen trimer, glycosaminoglycan binding, and response to chemical stimulus pathways (FDR P=5x10-4 - 5x10-7). Conclusions: Using a high throughput proteomics platform we have identified proteins that differentiate HIV-infected individuals with DD from those without DD, highlighting potential biomarkers and molecular mechanisms mediating DD in HIV for further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Diffuse myocardial fibrosis is uncommon in people with perinatally acquired human immunodeficiency virus infection.
- Author
-
Williams, Jason L., Hung, Frances, Jenista, Elizabeth, Barker, Piers, Chakraborty, Hrishikesh, Kim, Raymond, McCrary, Andrew W., Shah, Svati H., Thielman, Nathan, and Bloomfield, Gerald S.
- Subjects
- *
HIV infection transmission , *HIV infection complications , *CARDIOMYOPATHIES , *FIBROSIS , *MAGNETIC resonance imaging , *MANN Whitney U Test , *RISK assessment , *CELL survival , *DESCRIPTIVE statistics , *RESEARCH funding , *PERINATAL period , *DISEASE risk factors , *PREGNANCY - Abstract
Background: Cardiovascular disease (CVD) remains a leading cause of death in people living with HIV. Myocardial fibrosis is well-described in HIV infection acquired in adulthood. We evaluate the burden of fibrosis by cardiac magnetic resonance in people with perinatal HIV infection. Methods: Individuals with perinatally acquired HIV (pnHIV) diagnosed before 10 years-old and on antiretroviral treatment for ≥ 6 months were matched with uninfected controls. Patients with significant cardiometabolic co-morbidities and pregnancy were excluded. Diffuse fibrosis was assessed by cardiac magnetic resonance (CMR) with native T1 mapping for calculation of extracellular volume fraction (ECV). Viability was assessed with late gadolinium enhancement. The normality of fibrosis was assessed using the Komogrov-Smirnov test. Fibrosis between the groups was analyzed using a Mann-Whitney U test, as the data was not normally distributed. Statistical significance was defined as a p-valve < 0.05. Results: Fourteen adults with pnHIV group and 26 controls (71% female and 86% Black race) were assessed. The average (± standard deviation) age in the study group was 29 (± 4.3) years-old. All pnHIV had been on ART for decades. Demographic data, CMR functional/volumetric data, and pre-contrast T1 mapping values were similar between groups. Diastolic function was normal in 50% of pnHIV patients and indeterminate in most of the remainder (42%). There was no statistically significant difference in ECV between groups; p = 0.24. Conclusion: Perinatally-acquired HIV was not associated with diffuse myocardial fibrosis. Larger prospective studies with serial examinations are needed to determine whether pnHIV patients develop abnormal structure or function more often than unaffected controls. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Next Generation, Modifiable Cardiometabolic Biomarkers: Mitochondrial Adaptation and Metabolic Resilience: A Scientific Statement From the American Heart Association.
- Author
-
Mietus-Snyder, Michele, Perak, Amanda M., Cheng, Susan, Hayman, Laura L., Haynes, Norrisa, Meikle, Peter J., Shah, Svati H., and Suglia, Shakira F.
- Subjects
- *
DISEASE risk factors , *MITOCHONDRIA , *BIOMARKERS , *INSULIN resistance , *LIFE spans - Abstract
Cardiometabolic risk is increasing in prevalence across the life span with disproportionate ramifications for youth at socioeconomic disadvantage. Established risk factors and associated disease progression are harder to reverse as they become entrenched over time; if current trends are unchecked, the consequences for individual and societal wellness will become untenable. Interrelated root causes of ectopic adiposity and insulin resistance are understood but identified late in the trajectory of systemic metabolic dysregulation when traditional cardiometabolic risk factors cross current diagnostic thresholds of disease. Thus, children at cardiometabolic risk are often exposed to suboptimal metabolism over years before they present with clinical symptoms, at which point life-long reliance on pharmacotherapy may only mitigate but not reverse the risk. Leading-edge indicators are needed to detect the earliest departure from healthy metabolism, so that targeted, primordial, and primary prevention of cardiometabolic risk is possible. Better understanding of biomarkers that reflect the earliest transitions to dysmetabolism, beginning in utero, ideally biomarkers that are also mechanistic/causal and modifiable, is critically needed. This scientific statement explores emerging biomarkers of cardiometabolic risk across rapidly evolving and interrelated "omic" fields of research (the epigenome, microbiome, metabolome, lipidome, and inflammasome). Connections in each domain to mitochondrial function are identified that may mediate the favorable responses of each of the omic biomarkers featured to a heart-healthy lifestyle, notably to nutritional interventions. Fuller implementation of evidence-based nutrition must address environmental and socioeconomic disparities that can either facilitate or impede response to therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
- Author
-
Ghadimi, Kamrouz, Cappiello, Jhaymie L., Wright, Mary Cooter, Levy, Jerrold H., Bryner, Benjamin S., DeVore, Adam D., Schroder, Jacob N., Patel, Chetan B., Rajagopal, Sudarshan, Shah, Svati H., and Milano, Carmelo A.
- Subjects
- *
HEART assist devices , *CARDIAC surgery , *ARTIFICIAL blood circulation , *PROSTACYCLIN , *NITRIC oxide , *RENAL replacement therapy - Abstract
BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy. METHODS: In this double-blind trial, participants were stratified by assigned surgery and key preoperative prognostic features, then randomized to continuously receive either iEPO or iNO beginning at the time of separation from cardiopulmonary bypass with the continuation of treatment into the intensive care unit stay. The primary outcome was the composite RVF rate after both operations, defined after transplantation by the initiation of mechanical circulatory support for isolated RVF, and defined after left ventricular assist device implantation by moderate or severe right heart failure according to criteria from the Interagency Registry for Mechanically Assisted Circulatory Support. An equivalence margin of 15 percentage points was prespecified for between-group RVF risk difference. Secondary postoperative outcomes were assessed for treatment differences and included: mechanical ventilation duration; hospital and intensive care unit length of stay during the index hospitalization; acute kidney injury development including renal replacement therapy initiation; and death at 30 days, 90 days, and 1 year after surgery. RESULTS: Of 231 randomized participants who met eligibility at the time of surgery, 120 received iEPO, and 111 received iNO. Primary outcome occurred in 30 participants (25.0%) in the iEPO group and 25 participants (22.5%) in the iNO group, for a risk difference of 2.5 percentage points (two one-sided test 90% CI, -6.6% to 11.6%) in support of equivalence. There were no significant between-group differences for any of the measured postoperative secondary outcomes. CONCLUSIONS: Among patients undergoing major cardiac surgery for advanced heart failure, inhaled pulmonary-selective vasodilator treatment using iEPO was associated with similar risks for RVF development and development of other postoperative secondary outcomes compared with treatment using iNO. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. A Customizable and Peer-Reviewed Curriculum for Cardiovascular Genetics and Genomics.
- Author
-
Landstrom, Andrew P., Chahal, C. Anwar A., Roden, Dan M., Ho, Carolyn Y., and Shah, Svati H.
- Subjects
- *
GENETICS , *MEDICAL personnel , *GENETIC testing , *GENOMICS , *MEDICAL quality control , *MEDICAL students - Abstract
The article discusses the need for a comprehensive educational curriculum on cardiovascular genetics and genomics. It highlights the increasing relevance of genetics and genomics in patient care and the availability of genetic testing to a wider range of healthcare professionals. The lack of foundational education in cardiovascular genetics and genomics in training programs and medical curricula is identified as a gap that needs to be addressed. The article introduces the "From Concepts to Practice: A Guide to Cardiovascular Genomics" curriculum, which aims to provide genetic literacy and basic knowledge for healthcare professionals who care for patients with heritable cardiovascular disease. The curriculum consists of core modules and optional modules that can be customized based on the learner's needs. The article emphasizes the potential impact of the curriculum on advancing the field of cardiovascular medicine and research by improving the knowledge base of clinicians and researchers and facilitating the incorporation of cardiovascular genetics and genomics into clinical practice and research endeavors. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
26. Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
- Author
-
Selvaraj, Senthil, Kosiborod, Mikhail N., and Shah, Svati H.
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *BRAIN natriuretic factor , *DAPAGLIFLOZIN , *METABOLOMICS - Abstract
We thank Monzo and Melenovsky for their interest and comments on our study, which evaluated the association of metabolites and related pathways with several prespecified outcomes in a randomized, controlled trial of dapagliflozin versus placebo in patients with heart failure and reduced ejection fraction (DEFINE-HF [Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection]).[1],[2] As the authors note in their Letter to the Editor, they previously made an interesting observation that increased lactate uptake is associated with increased ketone uptake.[3] It is also worth noting that previous work by Nielsen and colleagues showed that exogenous ketones increase peripheral lactate production.[4] Although we agree that assessing changes in lactate levels with dapagliflozin treatment is worthy of further exploration, lactate levels were not profiled as part of the current study. 2022; 146: 808-818. doi: 10.1161/CIRCULATIONAHA.122.060402 3 Monzo L, Sedlacek K, Hromanikova K, Tomanova L, Borlaug BA, Jabor A, Kautzner J, Melenovsky V. Myocardial ketone body utilization in patients with heart failure: the impact of oral ketone ester. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
27. Biomarkers and Cardiovascular Disease.
- Author
-
Shah, Svati H. and De Lemos, James A.
- Subjects
- *
BIOMARKERS , *CARDIOVASCULAR diseases , *MEDICAL genetics , *DISEASE risk factors - Abstract
The authors reflect on various issues concerning the link between biomarkers and cardiovascular disease. They argue that studies that have combined genetics and biomarkers may help in establishing causality of a disease biomarker. They explain the concept of mendelian randomization, along with an overview of studies about biomarkers. The authors claim that biomarkers could be a risk factor and could be used to assess risk and individualize therapies.
- Published
- 2009
- Full Text
- View/download PDF
28. Genetics of cardiac repolarization.
- Author
-
Shah, Svati H. and Pitt, Geoffrey S.
- Subjects
- *
GENOMES , *HEART failure - Abstract
The article discusses a report published within the issue which focuses on the genome-wide studies of Arne Pfeufer and colleagues, and Christopher Newton-Cheh and colleagues which examines the association QT interval prolongation and arrhythmogenic disorders and risk for cardiac death.
- Published
- 2009
- Full Text
- View/download PDF
29. Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association.
- Author
-
Kwan, Tak W., Wong, Sally S., Hong, Yuling, Kanaya, Alka M., Khan, Sadiya S., Hayman, Laura L., Shah, Svati H., Welty, Francine K., Deedwania, Prakash C., Khaliq, Asma, and Palaniappan, Latha P.
- Subjects
- *
ASIAN Americans , *MEDICAL personnel , *CARDIOVASCULAR diseases , *TYPE 2 diabetes , *KOREANS - Abstract
Asian American individuals make up the fastest growing racial and ethnic group in the United States. Despite the substantial variability that exists in type 2 diabetes and atherosclerotic cardiovascular disease risk among the different subgroups of Asian Americans, the current literature, when available, often fails to examine these subgroups individually. The purpose of this scientific statement is to summarize the latest disaggregated data, when possible, on Asian American demographics, prevalence, biological mechanisms, genetics, health behaviors, acculturation and lifestyle interventions, pharmacological therapy, complementary alternative interventions, and their impact on type 2 diabetes and atherosclerotic cardiovascular disease. On the basis of available evidence to date, we noted that the prevalences of type 2 diabetes and stroke mortality are higher in all Asian American subgroups compared with non-Hispanic White adults. Data also showed that atherosclerotic cardiovascular disease risk is highest among South Asian and Filipino adults but lowest among Chinese, Japanese, and Korean adults. This scientific statement discusses the biological pathway of type 2 diabetes and the possible role of genetics in type 2 diabetes and atherosclerotic cardiovascular disease among Asian American adults. Challenges to provide evidence-based recommendations included the limited data on Asian American adults in risk prediction models, national surveillance surveys, and clinical trials, leading to significant research disparities in this population. The large disparity within this population is a call for action to the public health and clinical health care community, for whom opportunities for the inclusion of the Asian American subgroups should be a priority. Future studies of atherosclerotic cardiovascular disease risk in Asian American adults need to be adequately powered, to incorporate multiple Asian ancestries, and to include multigenerational cohorts. With advances in epidemiology and data analysis and the availability of larger, representative cohorts, furthering refining the Pooled Cohort Equations, in addition to enhancers, would allow better risk estimation in segments of the population. Last, this scientific statement provides individual- and community-level intervention suggestions for health care professionals who interact with the Asian American population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Prognostic value of CT-derived coronary artery disease characteristics varies by ASCVD risk: insights from the PROMISE trial.
- Author
-
Foldyna, Borek, Mayrhofer, Thomas, Lu, Michael T., Karády, Júlia, Kolossváry, Márton, Ferencik, Maros, Shah, Svati H., Pagidipati, Neha J., Douglas, Pamela S., and Hoffmann, Udo
- Subjects
- *
PROGNOSIS , *CORONARY artery disease , *CORONARY artery calcification , *CORONARY artery stenosis , *ANGINA pectoris - Abstract
Objectives: To compare the prognostic value of individual CT-derived coronary artery disease (CAD) characteristics across categories of clinical cardiovascular risk. Methods: The central core laboratory assessed coronary artery calcium (CAC), obstructive CAD (stenosis ≥ 50%), and high-risk plaque (HRP) in stable outpatients with suspected CAD enrolled in the PROMISE trial. Multivariable Cox regression models (endpoint: unstable angina, nonfatal myocardial infarction, or all-cause mortality; median follow-up: 2 years) were used to compare hazard ratios (HR) of the CT measures between low-borderline (< 7.5%) and moderate-high (≥ 7.5%) atherosclerotic cardiovascular disease (ASCVD) risk based on the pooled cohort equation. Results: Among 4356 included patients (aged 61 ± 8 years, 52% women), 67% had ASCVD risk ≥ 7.5%. Stratified by ASCVD risk, CAD ≥ 50% had nearly threefold greater HR in individuals with ASCVD < 7.5% (aHR, 6.85; 95% CI, 2.33–20.15; p < 0.001) vs. ASCVD ≥ 7.5% (aHR: 2.66, 95% CI: 1.67–4.25, p < 0.001; interaction p = 0.041). CAC predicted events solely in ASCVD ≥ 7.5% patients (aHR: 1.92, 95% CI: 1.01–3.63, p = 0.045; interaction p = 0.571), while HRP predicted events only in ASCVD < 7.5% (aHR: 3.11, 95% CI: 1.09–8.85, p = 0.034; interaction p = 0.034). Conclusions: Prognostic values of CT-derived CAD characteristics differ by ASCVD risk categories. While CAD ≥ 50% has the highest prognostic value regardless of ASCVD risk, CAC is prognostic in high and HRP in low ASCVD risk. These findings suggest that CAD ≥ 50% and HRP detection rather than CAC scoring may better risk-stratify symptomatic low-risk patients and thus potentially improve downstream care. Key Points: • Prognostic value of individual CT-derived CAD characteristics differs by categories of cardiovascular risk. • Presence of obstructive coronary artery stenosis ≥ 50% has the highest prognostic value regardless of cardiovascular risk. • Coronary artery calcium is independently prognostic in high and high-risk plaque features in low cardiovascular risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. An antiplatelet response gene expression signature is associated with bleeding.
- Author
-
Friede, Kevin A, Myers, Rachel A, Gales, Jordan, Zhbannikov, Ilya, Ortel, Thomas L, Shah, Svati H, Kraus, William E, Ginsburg, Geoffrey S, and Voora, Deepak
- Subjects
- *
GENE expression , *DISEASE risk factors , *PLATELET-rich plasma , *PLATELET aggregation inhibitors , *HEMORRHAGE - Abstract
Aims Gene expression biosignatures may hold promise to individualize antiplatelet therapy in conjunction with current guidelines and risk scores. The Aspirin Response Signature (ARS) score is comprised of a weighted sum of correlated, pro-thrombotic gene transcripts measured in whole blood. In prior work where volunteers were exposed to aspirin 325 mg daily, higher ARS score was associated with lower platelet function; separately, in a clinical cohort of patients, higher ARS scores were associated with increased risk of adverse cardiovascular events. To better understand this apparent paradox, we measured ARS gene expression and score in volunteers to determine aspirin dose–response and ticagrelor relationships with ARS score and separately in patients to assess whether ARS is associated with incident bleeding. Methods and results Blood samples were collected from volunteers (N = 188) who were exposed to 4 weeks of daily aspirin 81 mg, daily aspirin 325 mg, and/or twice-daily ticagrelor 90 mg. ARS scores were calculated from whole blood RNA qPCR, and platelet function and protein expression were assessed in platelet-rich plasma. In mixed linear regression models, aspirin 81 mg exposure was not associated with changes in ARS gene expression or score. Aspirin 325 mg exposure resulted in a 6.0% increase in ARS gene expression (P = 7.5 × 10−9 vs. baseline, P = 2.1 × 10−4 vs. aspirin 81 mg) and an increase in expression of platelet proteins corresponding to ARS genes. Ticagrelor exposure resulted in a 30.7% increase in ARS gene expression (P < 1 × 10−10 vs. baseline and each aspirin dose) and ARS score (P = 7.0 × 10−7 vs. baseline, P = 3.6 × 10−6 and 5.59 × 10−4 vs. aspirin 81 and 325 mg, respectively). Increases in ARS gene expression or score were associated with the magnitude of platelet inhibition across agents. To assess the association between ARS scores and incident bleeding, ARS scores were calculated in patients undergoing cardiac catheterization (N = 1421), of whom 25.4% experienced bleeding events over a median 6.2 years of follow-up. In a Cox model adjusting for demographics and baseline antithrombotic medication use, patients with ARS scores above the median had a higher risk of incident bleeding [hazard ratio 1.26 (95% CI 1.01–1.56), P = 0.038]. Conclusions The ARS is an Antiplatelet Response Signature that increases in response to greater platelet inhibition due to antiplatelet therapy and may represent a homeostatic mechanism to prevent bleeding. ARS scores could inform future strategies to prevent bleeding while maintaining antiplatelet therapy's benefit of ischaemic cardiovascular event protection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. EFFECT OF HEPARIN ADMINISTRATION ON METABOLOMIC PROFILES FROM SAMPLES OBTAINED DURING CARDIAC CATHETERIZATION
- Author
-
Brunner, Michael P., Shah, Svati H., Craig, Damian M., Bain, James R., Muehlbauer, Michael J., Newgard, Christopher B., Kraus, William E., Granger, Christopher B., Sketch, Michael H., and Newby, L. Kristin
- Published
- 2011
- Full Text
- View/download PDF
33. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease.
- Author
-
Shah, Svati H, Hauser, Elizabeth R, Bain, James R, Muehlbauer, Michael J, Haynes, Carol, Stevens, Robert D, Wenner, Brett R, Dowdy, Z Elaine, Granger, Christopher B, Ginsburg, Geoffrey S, Newgard, Christopher B, and Kraus, William E
- Subjects
- *
CARDIOVASCULAR diseases , *GENETIC disorders , *HERITABILITY , *AMINO acids , *FATTY acids - Abstract
Integration of genetic and metabolic profiling holds promise for providing insight into human disease. Coronary artery disease (CAD) is strongly heritable, but the heritability of metabolomic profiles has not been evaluated in humans. We performed quantitative mass spectrometry-based metabolic profiling in 117 individuals within eight multiplex families from the GENECARD study of premature CAD. Heritabilities were calculated using variance components. We found high heritabilities for amino acids (arginine, ornithine, alanine, proline, leucine/isoleucine, valine, glutamate/glutamine, phenylalanine and glycine; h2=0.33–0.80, P=0.005–1.9 × 10−16), free fatty acids (arachidonic, palmitic, linoleic; h2=0.48–0.59, P=0.002–0.00005) and acylcarnitines (h2=0.23–0.79, P=0.05–0.0000002). Principal components analysis was used to identify metabolite clusters. Reflecting individual metabolites, several components were heritable, including components comprised of ketones, β-hydroxybutyrate and C2-acylcarnitine (h2=0.61); short- and medium-chain acylcarnitines (h2=0.39); amino acids (h2=0.44); long-chain acylcarnitines (h2=0.39) and branched-chain amino acids (h2=0.27). We report a novel finding of high heritabilities of metabolites in premature CAD, establishing a possible genetic basis for these profiles. These results have implications for understanding CAD pathophysiology and genetics. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
34. The association of accelerated epigenetic age with all-cause mortality in cardiac catheterization patients as mediated by vascular and cardiometabolic outcomes.
- Author
-
Jiang, Rong, Hauser, Elizabeth R., Kwee, Lydia Coulter, Shah, Svati H., Regan, Jessica A., Huebner, Janet L., Kraus, Virginia B., Kraus, William E., and Ward-Caviness, Cavin K.
- Subjects
- *
CARDIAC catheterization , *MORTALITY , *PERIPHERAL vascular diseases , *CARDIAC patients , *AGE - Abstract
Background: Epigenetic age is a DNA methylation-based biomarker of aging that is accurate across the lifespan and a range of cell types. The difference between epigenetic age and chronological age, termed age acceleration (AA), is a strong predictor of lifespan and healthspan. The predictive capabilities of AA for all-cause mortality have been evaluated in the general population; however, its utility is less well evaluated in those with chronic conditions. Additionally, the pathophysiologic pathways whereby AA predicts mortality are unclear. We hypothesized that AA predicts mortality in individuals with underlying cardiovascular disease; and the association between AA and mortality is mediated, in part, by vascular and cardiometabolic measures. Methods: We evaluated 562 participants in an urban, three-county area of central North Carolina from the CATHGEN cohort, all of whom received a cardiac catheterization procedure. We analyzed three AA biomarkers, Horvath epigenetic age acceleration (HAA), phenotypic age acceleration (PhenoAA), and Grim age acceleration (GrimAA), by Cox regression models, to assess whether AAs were associated with all-cause mortality. We also evaluated if these associations were mediated by vascular and cardiometabolic outcomes, including left ventricular ejection fraction (LVEF), blood cholesterol concentrations, angiopoietin-2 (ANG2) protein concentration, peripheral artery disease, coronary artery disease, diabetes, and hypertension. The total effect, direct effect, indirect effect, and percentage mediated were estimated using pathway mediation tests with a regression adjustment approach. Results: PhenoAA (HR = 1.05, P < 0.0001), GrimAA (HR = 1.10, P < 0.0001) and HAA (HR = 1.03, P = 0.01) were all associated with all-cause mortality. The association of mortality and PhenoAA was partially mediated by ANG2, a marker of vascular function (19.8%, P = 0.016), and by diabetes (8.2%, P = 0.043). The GrimAA-mortality association was mediated by ANG2 (12.3%, P = 0.014), and showed weaker evidence for mediation by LVEF (5.3%, P = 0.065). Conclusions: Epigenetic age acceleration remains strongly predictive of mortality even in individuals already burdened with cardiovascular disease. Mortality associations were mediated by ANG2, which regulates endothelial permeability and angiogenic functions, suggesting that specific vascular pathophysiology may link accelerated epigenetic aging with increased mortality risks. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequity.
- Author
-
Nunes, Julio C., Carroll, Megan K., Mahaffey, Kenneth W., Califf, Robert M., Doraiswamy, P. Murali, Short, Sarah, Shah, Svati H., Swope, Susan, Williams, Donna, Hernandez, Adrian F., and Hong, David S.
- Subjects
- *
SOCIOECONOMIC status , *SOCIAL determinants of health , *ACTIVITIES of daily living , *ANXIETY , *DISEASE risk factors , *CROSS-sectional method , *SOCIAL classes , *QUESTIONNAIRES , *ANXIETY disorders , *LONGITUDINAL method , *PSYCHOSOCIAL factors - Abstract
Background: The General Anxiety Disorder-7 (GAD-7) questionnaire is a standard tool used for screening and follow-up of patients with Generalized Anxiety Disorder (GAD). Although it is generally accepted that anxiety correlates with clinical and psychosocial stressors, precise quantitative data is limited on the relations among GAD-7, traditional biomarkers, and other measures of health. Further research is needed about how GAD-7 relates to race, ethnicity, and socioeconomic status (SES) as an assembly. We determined how multiple demographic and socioeconomic data correlate with the participants' GAD-7 results when compared with laboratory, physical function, clinical, and other biological markers.Methods: The Project Baseline Health Study (BHS) is a prospective cohort of adults representing several populations in the USA. We analyzed a deeply phenotyped group of 2502 participants from that study. Measures of interest included: clinical markers or history of medical diagnoses; physical function markers including gait, grip strength, balance time, daily steps, and echocardiographic parameters; psychometric measurements; activities of daily living; socioeconomic characteristics; and laboratory results.Results: Higher GAD-7 scores were associated with female sex, younger age, and Hispanic ethnicity. Measures of low SES were also associated with higher scores, including unemployment, income ≤$25,000, and ≤12 years of education. After adjustment for 158 demographic, clinical, laboratory, and symptom characteristics, unemployment and overall higher SES risk scores were highly correlated with anxiety scores. Protective factors included Black race and older age.Limitations: Correlations identified in this cross-sectional study cannot be used to infer causal relationships; further, we were not able to account for possible use of anxiety treatments by study participants.Conclusions: These findings highlight the importance of understanding anxiety as a biopsychosocial entity. Clinicians and provider organizations need to consider both the physical manifestations of the disorder and their patients' social determinants of health when considering treatment pathways and designing interventions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Coupled myovascular expansion directs cardiac growth and regeneration.
- Author
-
DeBenedittis, Paige, Karpurapu, Anish, Henry, Albert, Thomas, Michael C., McCord, Timothy J., Brezitski, Kyla, Prasad, Anil, Baker, Caroline E., Kobayashi, Yoshihiko, Shah, Svati H., Kontos, Christopher D., Rao Tata, Purushothama, Lumbers, R. Thomas, and Karra, Ravi
- Subjects
- *
CARDIAC regeneration , *HEART cells , *ENDOTHELIAL cells , *HUMAN growth , *SNAKE venom - Abstract
Heart regeneration requires multiple cell types to enable cardiomyocyte (CM) proliferation. How these cells interact to create growth niches is unclear. Here, we profile proliferation kinetics of cardiac endothelial cells (CECs) and CMs in the neonatal mouse heart and find that they are spatiotemporally coupled. We show that coupled myovascular expansion during cardiac growth or regeneration is dependent upon VEGF-VEGFR2 signaling, as genetic deletion of Vegfr2 from CECs or inhibition of VEGFA abrogates both CEC and CM proliferation. Repair of cryoinjury displays poor spatial coupling of CEC and CM proliferation. Boosting CEC density after cryoinjury with virus encoding Vegfa enhances regeneration. Using Mendelian randomization, we demonstrate that circulating VEGFA levels are positively linked with human myocardial mass, suggesting that Vegfa can stimulate human cardiac growth. Our work demonstrates the importance of coupled CEC and CM expansion and reveals a myovascular niche that may be therapeutically targeted for heart regeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
- Author
-
Selvaraj, Senthil, Fu, Zhuxuan, Jones, Philip, Kwee, Lydia C., Windsor, Sheryl L., Ilkayeva, Olga, Newgard, Christopher B., Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Lanfear, David E., Nassif, Michael E., Javaheri, Ali, Mentz, Robert J., Kosiborod, Mikhail N., Shah, Svati H., and DEFINE-HF Investigators
- Subjects
- *
BENZENE , *LEFT ventricular dysfunction , *CARDIOMYOPATHIES , *SODIUM , *GLYCOSIDES , *TYPE 2 diabetes , *QUALITY of life , *QUESTIONNAIRES , *RESEARCH funding , *STROKE volume (Cardiac output) , *GLUCOSE , *HEART failure , *ACIDOSIS , *FATTY acids , *KETONES , *DISEASE complications - Abstract
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of benefit are not well defined. We sought to investigate the relationships between sodium-glucose cotransporter-2 inhibitor treatment, changes in metabolic pathways, and outcomes using targeted metabolomics.Methods: DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) was a placebo-controlled trial of dapagliflozin in HFrEF. We performed targeted mass spectrometry profiling of 63 metabolites (45 acylcarnitines [markers of fatty acid oxidation], 15 amino acids, and 3 conventional metabolites) in plasma samples at randomization and 12 weeks. Using mixed models, we identified principal components analysis-defined metabolite clusters that changed differentially with treatment and examined the relationship between change in metabolite clusters and change in Kansas City Cardiomyopathy Questionnaire scores and NT-proBNP (N-terminal probrain natriuretic peptide). Models were adjusted for relevant clinical covariates and nominal P<0.05 with false discovery rate-adjusted P<0.10 was used to determine statistical significance.Results: Among the 234 DEFINE-HF participants with targeted metabolomic data, the mean age was 62.0±11.1 years, 25% were women, 38% were Black, and mean ejection fraction was 27±8%. Dapagliflozin increased ketone-related and short-chain acylcarnitine as well as medium-chain acylcarnitine principal components analysis-defined metabolite clusters compared with placebo (nominal P=0.01, false discovery rate-adjusted P=0.08 for both clusters). However, ketosis (β-hydroxybutyrate levels >500 μmol/L) was achieved infrequently (3 [2.5%] in dapagliflozin arm versus 1 [0.9%] in placebo arm) and supraphysiologic levels were not observed. Increases in long-chain acylcarnitine, long-chain dicarboxylacylcarnitine, and aromatic amino acid metabolite clusters were associated with decreases in Kansas City Cardiomyopathy Questionnaire scores (ie, worse quality of life) and increases in NT-proBNP levels, without interaction by treatment group.Conclusions: In this study of targeted metabolomics in a placebo-controlled trial of sodium-glucose cotransporter-2 inhibitors in HFrEF, we observed effects of dapagliflozin on key metabolic pathways, supporting a role for altered ketone and fatty acid biology with sodium-glucose cotransporter-2 inhibitors in patients with HFrEF. Only physiologic levels of ketosis were observed. In addition, we identified several metabolic biomarkers associated with adverse HFrEF outcomes.Registration: URL: https://www.Clinicaltrials: gov; Unique identifier: NCT02653482. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. Multi-dimensional characterization of prediabetes in the Project Baseline Health Study.
- Author
-
Chatterjee, Ranee, Kwee, Lydia Coulter, Pagidipati, Neha, Koweek, Lynne H., Mettu, Priyatham S., Haddad, Francois, Maron, David J., Rodriguez, Fatima, Mega, Jessica L., Hernandez, Adrian, Mahaffey, Kenneth, Palaniappan, Latha, and Shah, Svati H.
- Subjects
- *
PREDIABETIC state , *CORONARY artery calcification , *LEUCOCYTES , *FALSE discovery rate , *ERYTHROCYTES , *POLYSOMNOGRAPHY , *RED blood cell transfusion - Abstract
Background: We examined multi-dimensional clinical and laboratory data in participants with normoglycemia, prediabetes, and diabetes to identify characteristics of prediabetes and predictors of progression from prediabetes to diabetes or reversion to no diabetes. Methods: The Project Baseline Health Study (PBHS) is a multi-site prospective cohort study of 2502 adults that conducted deep clinical phenotyping through imaging, laboratory tests, clinical assessments, medical history, personal devices, and surveys. Participants were classified by diabetes status (diabetes [DM], prediabetes [preDM], or no diabetes [noDM]) at each visit based on glucose, HbA1c, medications, and self-report. Principal component analysis (PCA) was performed to create factors that were compared across groups cross-sectionally using linear models. Logistic regression was used to identify factors associated with progression from preDM to DM and for reversion from preDM to noDM. Results: At enrollment, 1605 participants had noDM; 544 had preDM; and 352 had DM. Over 4 years of follow-up, 52 participants with preDM developed DM and 153 participants reverted to noDM. PCA identified 33 factors composed of clusters of clinical variables; these were tested along with eight individual variables identified a priori as being of interest. Six PCA factors and six a priori variables significantly differed between noDM and both preDM and DM after false discovery rate adjustment for multiple comparisons (q < 0.05). Of these, two factors (one comprising glucose measures and one of anthropometry and physical function) demonstrated monotonic/graded relationships across the groups, as did three a priori variables: ASCVD risk, coronary artery calcium, and triglycerides (q < 10–21 for all). Four factors were significantly different between preDM and noDM, but concordant or similar between DM and preDM: red blood cell indices (q = 8 × 10-10), lung function (q = 2 × 10-6), risks of chronic diseases (q = 7 × 10-4), and cardiac function (q = 0.001), along with a priori variables of diastolic function (q = 1 × 10-10), sleep efficiency (q = 9 × 10-6) and sleep time (q = 6 × 10-5). Two factors were associated with progression from prediabetes to DM: anthropometry and physical function (OR [95% CI]: 0.6 [0.5, 0.9], q = 0.04), and heart failure and c-reactive protein (OR [95% CI]: 1.4 [1.1, 1.7], q = 0.02). The anthropometry and physical function factor was also associated with reversion from prediabetes to noDM: (OR [95% CI]: 1.9 [1.4, 2.7], q = 0.02) along with a factor of white blood cell indices (OR [95% CI]: 0.6 [0.4, 0.8], q = 0.02), and the a priori variables ASCVD risk score (OR [95% CI]: 0.7 [0.6, 0.9] for each 0.1 increase in ASCVD score, q = 0.02) and triglycerides (OR [95% CI]: 0.9 [0.8, 1.0] for each 25 mg/dl increase, q = 0.05). Conclusions: PBHS participants with preDM demonstrated pathophysiologic changes in cardiac, pulmonary, and hematology measures and declines in physical function and sleep measures that precede DM; some changes predicted an increased risk of progression to DM. A factor with measures of anthropometry and physical function was the most important factor associated with progression to DM and reversion to noDM. Future studies may determine whether these changes elucidate pathways of progression to DM and related complications and whether they can be used to identify individuals at higher risk of progression to DM for targeted preventive interventions. Trial registration ClinicalTrials.gov NCT03154346 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.
- Author
-
Lerman, Joseph B., Giamberardino, Stephanie N., Hernandez, Adrian F., Felker, G. Michael, Shah, Svati H., and McGarrah, Robert W.
- Subjects
- *
TYPE 2 diabetes , *VENTRICULAR ejection fraction , *INDUCTIVELY coupled plasma mass spectrometry , *HEART failure , *UREA , *METABOLITES - Abstract
Heart failure with reduced ejection fraction (HFrEF) is increasingly treated with medications for type 2 diabetes mellitus (T2DM). Whether metabolic derangements in HFrEF and T2DM are associated with differential outcomes remains unclear. Therefore, understanding molecular pathways in HFrEF and T2DM and their effects on clinical endpoints is important. The FIGHT trial randomized 300 individuals with HFrEF and a recent HF hospitalization to liraglutide (a GLP-1 receptor agonist) versus placebo to assess effects on mortality, HF rehospitalization, and 6-month change in NT-ProBNP. Although the trial showed no clinical benefit of liraglutide, the trial population was highly enriched for individuals with T2DM. Sixty metabolites were quantified via mass spectrometry in plasma from 254 FIGHT participants (N = 147 (57.9%) with T2DM). Principal components analysis reduced the high number of correlated metabolites into uncorrelated factors. The association of factor levels with 90-day changes in 6-min walk distance (6MWD) and NT-proBNP, and with time to mortality or HF hospitalization were evaluated. There were no changes in metabolite factors according to treatment assignment. However, in analyses stratified by T2DM status, changes in five plasma metabolite factors correlated with changes in functional outcomes beyond adjustment: factor 2 (branched-chain amino acids [BCAA]) correlated with changes in NT-proBNP (ρ = − 0.291, p = 4 × 10–4) and 6MWD (ρ= 0.265, p = 0.011); factor 1 (medium-chain acylcarnitines; ρ = 0.220, p = 0.008), factor 4 (long-chain dicarboxylacylcarnitines; ρ = 0.191, p = 0.019), factor 5 (long-chain acylcarnitines; ρ = 0.198, p = 0.017), and factor 8 (urea cycle metabolites; ρ = − 0.239, p = 4 × 10–3), correlated with change in NT-proBNP. Factor 4 was associated with time-to-event (HR = 1.513 [95% CI 1.208–1.896], p = 3 × 10–4) with a trend towards stronger prognostic effect in T2DM (T2DM: p = 1 × 10–3, non-T2DM: p = 0.1). We identified metabolites of BCAA, urea cycle and fatty acid metabolism as biomarkers of HFrEF outcomes, with observed differences in HFrEF patients with T2DM. Such biomarkers might enable future diagnostic or therapeutic interventions in individuals with HFrEF and T2DM. Trial Registration: Clinicaltrials.gov. Identifier: NCT01800968. First posted: February 28, 2013. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization.
- Author
-
Smilowitz, Nathaniel R., Cornwell, MacIntosh, Offerman, Erik J., Rockman, Caron B., Shah, Svati H., Newman, Jonathan D., Ruggles, Kelly, Voora, Deepak, and Berger, Jeffrey S.
- Subjects
- *
MYOCARDIAL injury , *LEG injuries , *MAJOR adverse cardiovascular events , *LEG amputation , *SURGICAL complications , *MYOCARDIAL infarction - Abstract
Myocardial injury after non-cardiac surgery (MINS) is common. We investigated the incidence and outcomes of MINS, and mechanistic underpinnings using pre-operative whole blood gene expression profiling in a prospective cohort study of individuals undergoing lower extremity revascularization (LER) for peripheral artery disease (PAD). Major adverse cardiovascular and limb events (MACLE) were defined as a composite of death, myocardial infarction, stroke, major lower extremity amputation or reoperation. Among 226 participants undergoing LER, MINS occurred in 53 (23.5%). Patients with MINS had a greater incidence of major adverse cardiovascular events (49.1% vs. 22.0%, adjusted HR 1.87, 95% CI 1.07–3.26) and MACLE (67.9% vs. 44.5%; adjusted HR 1.66, 95% CI 1.08–2.55) at median 20-month follow-up. Pre-operative whole blood transcriptome profiling of a nested matched MINS case–control cohort (n = 41) identified upregulation of pathways related to platelet alpha granules and coagulation in patients who subsequently developed MINS. Thrombospondin 1 (THBS1) mRNA expression was 60% higher at baseline in patients who later developed MINS, and was independently associated with long-term cardiovascular events in the Duke Catheterization Genetics biorepository cohort. In conclusion, pre-operative THBS1 mRNA expression is higher in patients who subsequently develop MINS and is associated with incident cardiovascular events. Pathways related to platelet activity and coagulation associated with MINS provide novel insights into mechanisms of myocardial injury. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Urine tricarboxylic acid cycle signatures of early-stage diabetic kidney disease.
- Author
-
Lunyera, Joseph, Diamantidis, Clarissa J., Bosworth, Hayden B., Patel, Uptal D., Bain, James, Muehlbauer, Michael J., Ilkayeva, Olga, Nguyen, Maggie, Sharma, Binu, Ma, Jennie Z., Shah, Svati H., and Scialla, Julia J.
- Subjects
- *
DIABETIC nephropathies , *KREBS cycle , *URINE , *KIDNEY physiology , *PRINCIPAL components analysis - Abstract
Introduction: Urine tricarboxylic acid (TCA) cycle organic anions (OAs) are elevated in diabetes and may be biomarkers for diabetic kidney disease (DKD) progression. Objectives: We assessed associations of 10 urine TCA cycle OAs with estimated glomerular filtration rate (eGFR) and eGFR slope. Methods: This study is ancillary to the Simultaneous Risk Factor Control Using Telehealth to SlOw Progression of Diabetic Kidney Disease (STOP-DKD) Trial—a randomized trial of pharmacist-led medication and behavior management in 281 patients with early to moderate DKD at Duke from 2014 to 2015. We used linear mixed models to assess associations of urine TCA cycle OAs with outcomes and modelled TCA cycle OAs as: (1) the average of z-scores for each OA; and (2) principal component (PC) scores derived by principal component analysis (PCA). Untargeted urine metabolomics were added for additional discovery. Results: Among 132 participants with 24 h urine samples (50% men; 58% Black; mean age 64 years [SD 9]; mean eGFR 74 ml/min/1.73m2 [SD 21] and median urine albumin-to-creatinine [UACR] 20 mg/g [IQR 8–95]), PCA identified 3 OA metabolite PCs. Malate, fumarate, pyruvate, α-ketoglutarate, lactate, succinate and citrate/isocitrate loaded positively on PC1; methylsuccinate, ethylmalonate and succinate loaded positively on PC2; and methylmalonate, ethylmalonate and citrate/isocitrate loaded negatively on PC3. Over a median follow-up of 1.8 years (IQR, 1.2 to 2.2), higher average OA z-score was strongly associated with higher eGFR after covariate adjustment (p = 0.01), but not with eGFR slope (p = 0.9). Higher PC3, but not other PCs, was associated with lower eGFR (p < 0.001). Conditional random forests and smooth clipped absolute deviation models confirmed methylmalonate, citrate/isocitrate, and ethylmalonate, and added lactate as top ranked metabolites in models of baseline eGFR (R-squared 0.32 and 0.33, respectively). Untargeted urine metabolites confirmed association of urine TCA cycle OAs with kidney function. Conclusion: Thus, lower urine TCA cycle OAs, most notably lower methylmalonate, ethylmalonate and citrate/isocitrate, are potential indicators of kidney impairment in early stage DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population
- Author
-
Lappé, Jason M., Horne, Benjamin D., Shah, Svati H., May, Heidi T., Muhlestein, Joseph B., Lappé, Donald L., Kfoury, Abdallah G., Carlquist, John F., Budge, Deborah, Alharethi, Rami, Bair, Tami L., Kraus, William E., and Anderson, Jeffrey L.
- Subjects
- *
CORONARY disease , *C-reactive protein , *ERYTHROCYTES , *MORTALITY , *INFLAMMATION , *PROPORTIONAL hazards models , *PREDICTION models , *POPULATION biology , *PATIENTS - Abstract
Abstract: Background: Red cell distribution width (RDW) is associated with morbidity and mortality in coronary artery disease (CAD), but the connection of RDW with chronic inflammation is equivocal. Methods: In 1,489 patients with CAD and 8.4–15.2years of follow-up all-cause mortality and RDW were studied using Cox regression. RDW and its associations with inflammation, liver function, renal function, and body mass were assessed. A population of 449 normal (No-CAD) patients also was evaluated. Results: RDW predicted all-cause mortality in a step-wise manner (HR=1.37 per quintile; 95% CI=1.29, 1.46; p-trend<0.001). A significant but meaningless correlation between RDW and high-sensitivity C-reactive protein (hsCRP) was identified (r=0.181; p<0.001). With full adjustment, RDW remained significant (p-trend<0.001) and the strongest predictor of mortality among all factors included in the model. RDW also strongly predicted all-cause mortality in the normal control population (HR=1.33 per quintile, CI=1.15, 1.55; p-trend<0.001), but hsCRP did not predict mortality among normal controls. Conclusions: RDW was associated with mortality in patients with CAD and may provide clinically useful prognostication. Although RDW was correlated with hsCRP, they were independent predictors of mortality. RDW has been incorporated into risk prediction tool using data from basic chemistries available at: http://intermountainhealthcare.org/IMRS. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
43. Exploration of a Hypothesized Independent Association of a Common 9p21.3 Gene Variant and Ischemic Stroke in Patients with and without Angiographic Coronary Artery Disease.
- Author
-
Plant, Sheila R., Samsa, Greg P., Shah, Svati H., and Goldstein, Larry B.
- Subjects
- *
ISCHEMIA , *CEREBROVASCULAR disease , *ANGIOGRAPHY , *GENETIC polymorphisms , *CORONARY arteries , *CHROMOSOMES - Abstract
Background: Single-nucleotide polymorphisms (SNPs) at the chromosome 9p21.3 locus are associated with coronary artery disease (CAD). An association of this genomic region with ischemic stroke independent of its effect on CAD could suggest an additional, stroke-specific pathophysiological relationship. Methods: Medical record review was used to identify 548 patients without a history of cerebrovascular disease and 232 who had a verified ischemic stroke or transient ischemic attack (TIA) from the Duke CATHGEN biorepository of patients who had a cardiac catheterization. ANCOVA and multivariable logistic regression modeling were performed to determine independent genetic associations between the key chromosome 9p21.3 SNP, rs10757278, and ischemic stroke by comparing allele frequencies between 229 patients with stroke or TIA and an equal number of matched nonstroke controls, adjusting for other risk factors. In a secondary analysis, controls were further divided based on the presence (n = 353) or absence (n = 195) of angiographic CAD. Results: Allele frequencies were similar between patients with and without a history of ischemic stroke in both additive (p = 0.83) and dominant (p = 0.92) models of genetic risk. There was no association between rs10757278 allele frequency and stroke status based on the presence or absence of angiographically demonstrated CAD in nonstroke controls (ANCOVA, p = 0.99). Conclusion: These results provide no evidence of a stroke-specific association of the 9p21.3 locus regardless of the presence or absence of angiographic CAD and highlight the need for larger studies to further evaluate this hypothesized relationship. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
44. Peakwide Mapping on Chromosome 3q13 Identifies the Kalirin Gene as a Novel Candidate Gene for Coronary Artery Disease.
- Author
-
Liyong Wang, Hauser, Elizabeth R., Shah, Svati H., Pericak-Vance, Margaret A., Haynes, Carol, Crosslin, David, Harris, II, Marco, Nelson, Sarah, Hale, A. Brent, Granger, Christopher B., Haines, Jonathan L., Jones, Christopher J. H., Crossman, David, Seo, David, Gregory, Simon G., Kraus, William E., Goldschmidt-Clermont, Pascal J., and Vance, Jeffery M.
- Subjects
- *
CORONARY disease , *CHROMOSOMES , *GENES , *GENETIC polymorphisms , *ATHEROSCLEROSIS , *NITRIC oxide - Abstract
A susceptibility locus for coronary artery disease (CAD) has been mapped to chromosome 3q13-21 in a linkage study of early-onset CAD. We completed an association-mapping study across the 1-LOD-unit-down supporting interval, using two independent white case-control data sets (CATHGEN, initial and validation) to evaluate association under the peak. Single-nucleotide polymorphisms (SNPs) evenly spaced at 100-kb intervals were screened in the initial data set (N = 468). Promising SNPs (P < .1) were then examined in the validation data set (N = 514). Significant findings (P <.05) in the combined initial and validation data sets were further evaluated in multiple independent data sets, including a family-based data set (N = 2,954), an African American case-control data set (N = 190), and an additional white control data set (N = 255). The association between genotype and aortic atherosclerosis was examined in 145 human aortas. The peakwide survey found evidence of association in SNPs from multiple genes. The strongest associations were found in three SNPs from the kalirin (KALRN) gene, especially in patients with early-onset CAD (P = .00001-00028 in the combined CATHGEN data sets). In-depth investigation of the gene found that an intronic SNP, rs9289231, was associated with early-onset CAD in all white data sets examined (P < .05). In the joint analysis of all white early-onset CAD cases (N = 332) and controls (N = 546), rs9289231 was highly significant (P = .00008), with an odds-ratio estimate of 2.1. Furthermore, the risk allele of this SNP was associated with atherosclerosis burden (P = .03) in 145 human aortas. KALRN is a protein with many functions, including the inhibition of inducible nitric oxide synthase and guanine-exchange-factor activity. KALRN and two other associated genes identified in this study (CDGAP and MYLK) belong to the Rho GTPase-signaling pathway. Our data suggest the importance of the KALRN gene and the Rho GTPase-signaling pathway in the pathogenesis of CAD. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
45. Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation.
- Author
-
Truby, Lauren K., Kwee, Lydia Coulter, Agarwal, Richa, Grass, Elizabeth, DeVore, Adam D., Patel, Chetan B., Chen, Dongfeng, Schroder, Jacob N., Bowles, Dawn, Milano, Carmelo A., Shah, Svati H., and Holley, Christopher L.
- Subjects
- *
HEART transplantation , *ARTIFICIAL blood circulation , *BIOMARKERS , *PROTEOMICS , *HEART transplant recipients - Abstract
Clinical models to identify patients at high risk of primary graft dysfunction (PGD) after heart transplantation (HT) are limited, and the underlying pathophysiology of this common post-transplant complication remains poorly understood. We sought to identify whether pre-transplant levels of circulating proteins reporting on immune activation and inflammation are associated with incident PGD. The study population consisted of 219 adult heart transplant recipients identified between 2016 and 2020 at Duke University Medical Center, randomly divided into derivation (n = 131) and validation (n = 88) sets. PGD was defined using modified ISHLT criteria. Proteomic profiling was performed using Olink panels (n = 354 proteins) with serum samples collected immediately prior to transplantation. Association between normalized relative protein expression and PGD was tested using univariate and multivariable (recipient age, creatinine, mechanical circulatory support, and sex; donor age; ischemic time) models. Significant proteins identified in the derivation set (p < 0.05 in univariate models), were then tested in the validation set. Pathway enrichment analysis was used to test candidate biological processes. The predictive performance of proteins was compared to that of the RADIAL score. Nine proteins were associated with PGD in univariate models in the derivation set. Of these, only CLEC4C remained associated with PGD in the validation set after Bonferroni correction (OR [95% CI] = 3.04 [1.74,5.82], p = 2.8 × 10−4). Patterns of association were consistent for CLEC4C in analyses stratified by biventricular/left ventricular and isolated right ventricular PGD. Pathway analysis identified interferon-alpha response and C-type lectin signaling as significantly enriched biologic processes. The RADIAL score was a poor predictor of PGD (AUC = 0.55). CLEC4C alone (AUC = 0.66, p = 0.048) and in combination with the clinical covariates from the multivariable model (AUC = 0.69, p = 0.018) improved discrimination for the primary outcome. Pre-transplantation circulating levels of CLEC4C, a protein marker of plasmacytoid dendritic cells (pDCs), may identify HT recipients at risk for PGD. Further studies are needed to better understand the potential role pDCs and the innate immune response in PGD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy.
- Author
-
Truby, Lauren K., Regan, Jessica A., Giamberardino, Stephanie N., Ilkayeva, Olga, Bain, James, Newgard, Christopher B., O'Connor, Christopher M., Felker, G. Michael, Kraus, William E., McGarrah, Robert W., and Shah, Svati H.
- Subjects
- *
HEART failure , *AEROBIC capacity , *TREATMENT effectiveness , *MORTALITY , *CLINICAL trials - Abstract
Background: Whether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and clinical outcomes, remains unknown. The objective of the current study was to use metabolomic profiling to identify biomarkers that report on exercise capacity, clinical outcomes, and differential response to exercise in HF patients with and without DM. Methods: Targeted mass spectrometry was used to quantify metabolites in plasma from participants in the heart failure: a controlled trial investigating outcomes of exercise training (HF-ACTION) trial. Principal components analysis was used to identify 12 uncorrelated factors. The association between metabolite factors, diabetes status, exercise capacity, and time to the primary clinical outcome of all-cause mortality or all-cause hospitalization was assessed. Results: A total of 664 participants were included: 359 (54%) with DM. LCAC factor levels were associated with baseline exercise capacity as measured by peak oxygen consumption (beta 0.86, p = 2 × 10−7, and were differentially associated in participants with and without DM (beta 1.58, p = 8 × 10−8 vs. 0.67, p = 9 × 10−4, respectively; p value for interaction = 0.012). LCAC levels changed to a lesser extent in participants with DM after exercise (mean ∆ 0.09, p = 0.24) than in those without DM (mean ∆ 0.16, p = 0.08). In univariate and multivariate modeling, LCAC factor levels were associated with time to the primary outcome (multivariate HR 0.80, p = 2.74 × 10−8), and were more strongly linked to outcomes in diabetic participants (HR 0.64, p = 3.21 × 10−9 v. HR 0.90, p = 0.104, p value for interaction = 0.001). When analysis was performed at the level of individual metabolites, C16, C16:1, C18, and C18:1 had the greatest associations with both exercise capacity and outcomes, with higher levels associated with worse outcomes. Similar associations with time to the primary clinical outcome were not found in a control group of patients without HF from the CATHeterization GENetics (CATHGEN) study. Conclusions: LCAC biomarkers are associated with exercise status and clinical outcomes differentially in HF patients with and without DM. Impaired fatty acid substrate utilization and mitochondrial dysfunction both at the level of the skeletal muscle and the myocardium may explain the decreased exercise capacity, attenuated response to exercise training, and poor clinical outcomes seen in patients with HF and DM. Trial Registration clinicaltrials.gov Identifier: NCT00047437. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Return of individual research results: What do participants prefer and expect?
- Author
-
Sayeed, Sabina, Califf, Robert, Green, Robert, Wong, Celeste, Mahaffey, Kenneth, Gambhir, Sanjiv Sam, Mega, Jessica, Patrick-Lake, Bray, Frazier, Kaylyn, Pignone, Michael, Hernandez, Adrian, Shah, Svati H., Fan, Alice C., Krüg, Sarah, Shaack, Terry, Shore, Scarlet, Spielman, Susie, Eckstrand, Julie, and Wong, Charlene A.
- Subjects
- *
DISEASE risk factors , *CARDIAC imaging , *MEDICAL personnel , *HUMAN research subjects , *OLDER people - Abstract
Newer data platforms offer increased opportunity to share multidimensional health data with research participants, but the preferences of participants for which data to receive and how is evolving. Our objective is to describe the preferences and expectations of participants for the return of individual research results within Project Baseline Health Study (PBHS). The PBHS is an ongoing, multicenter, longitudinal cohort study with data from four initial enrollment sites. PBHS participants are recruited from the general population along with groups enriched for heart disease and cancer disease risk. Cross-sectional data on return of results were collected in 2017–2018 from an (1) in-person enrollment survey (n = 1,890), (2) benchmark online survey (n = 1,059), and (3) participant interviews (n = 21). The main outcomes included (1) preferences for type of information to be added next to returned results, (2) participant plans for sharing returned results with a non-study clinician, and (3) choice to opt-out of receiving genetic results. Results were compared by sociodemographic characteristics. Enrollment and benchmark survey respondents were 57.1% and 53.5% female, and 60.0% and 66.2% white, respectively. Participants preferred the following data types be added to returned results in the future: genetics (29.9%), heart imaging, (16.4%), study watch (15.8%), and microbiome (13.3%). Older adults (OR 0.60, 95% CI: 0.41–0.87) were less likely to want their genetic results returned next. Forty percent of participants reported that they would not share all returned results with their non–study clinicians. Black (OR 0.64, 95% CI 0.43–0.95) and Asian (OR 0.47, 95% CI 0.30–0.73) participants were less likely, and older participants more likely (OR 1.45–1.61), to plan to share all results with their clinician than their counterparts. At enrollment, 5.8% of participants opted out of receiving their genetics results. The study showed that substantial heterogeneity existed in participant's preferences and expectations for return of results, and variations were related to sociodemographic characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Metabolomic profiling identifies complex lipid species and amino acid analogues associated with response to weight loss interventions.
- Author
-
Bihlmeyer, Nathan A., Kwee, Lydia Coulter, Clish, Clary B., Deik, Amy Anderson, Gerszten, Robert E., Pagidipati, Neha J., Laferrère, Blandine, Svetkey, Laura P., Newgard, Christopher B., Kraus, William E., and Shah, Svati H.
- Subjects
- *
WEIGHT loss , *AMINO acids , *METABOLOMICS , *OBESITY , *INSULIN resistance - Abstract
Obesity is an epidemic internationally. While weight loss interventions are efficacious, they are compounded by heterogeneity with regards to clinically relevant metabolic responses. Thus, we sought to identify metabolic biomarkers that are associated with beneficial metabolic changes to weight loss and which distinguish individuals with obesity who would most benefit from a given type of intervention. Liquid chromatography mass spectrometry-based profiling was used to measure 765 metabolites in baseline plasma from three different weight loss studies: WLM (behavioral intervention, N = 443), STRRIDE-PD (exercise intervention, N = 163), and CBD (surgical cohort, N = 125). The primary outcome was percent change in insulin resistance (as measured by the Homeostatic Model Assessment of Insulin Resistance [%ΔHOMA-IR]) over the intervention. Overall, 92 individual metabolites were associated with %ΔHOMA-IR after adjustment for multiple comparisons. Concordantly, the most significant metabolites were triacylglycerols (TAGs; p = 2.3e-5) and diacylglycerols (DAGs; p = 1.6e-4), with higher baseline TAG and DAG levels associated with a greater improvement in insulin resistance with weight loss. In tests of heterogeneity, 50 metabolites changed differently between weight loss interventions; we found amino acids, peptides, and their analogues to be most significant (4.7e-3) in this category. Our results highlight novel metabolic pathways associated with heterogeneity in response to weight loss interventions, and related biomarkers which could be used in future studies of personalized approaches to weight loss interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain.
- Author
-
Kammerlander, Andreas A., Mayrhofer, Thomas, Ferencik, Maros, Pagidipati, Neha J., Karady, Julia, Ginsburg, Geoffrey S., Lu, Michael T., Bittner, Daniel O., Puchner, Stefan B., Bihlmeyer, Nathan A., Meyersohn, Nandini M., Emami, Hamed, Shah, Svati H., Douglas, Pamela S., Hoffmann, Udo, and PROMISE Investigators
- Subjects
- *
CARDIOVASCULAR diseases , *COMPUTED tomography , *CORONARY disease , *CHEST pain , *METABOLIC syndrome , *PHENOTYPES - Abstract
Objective: Obesity and metabolic syndrome are associated with major adverse cardiovascular events (MACE). However, whether distinct metabolic phenotypes differ in risk for coronary artery disease (CAD) and MACE is unknown. We sought to determine the association of distinct metabolic phenotypes with CAD and MACE.Research Design and Methods: We included patients from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) who underwent coronary computed tomography (CT) angiography. Obesity was defined as a BMI ≥30 kg/m2 and metabolically healthy as less than or equal to one metabolic syndrome component except diabetes, distinguishing four metabolic phenotypes: metabolically healthy/unhealthy and nonobese/obese (MHN, MHO, MUN, and MUO). Differences in severe calcification (coronary artery calcification [CAC] ≥400), severe CAD (≥70% stenosis), high-risk plaque (HRP), and MACE were assessed using adjusted logistic and Cox regression models.Results: Of 4,381 patients (48.4% male, 60.5 ± 8.1 years of age), 49.4% were metabolically healthy (30.7% MHN and 18.7% MHO) and 50.6% unhealthy (22.3% MUN and 28.4% MUO). MHO had similar coronary CT findings as compared with MHN (severe CAC/CAD and HRP; P > 0.36 for all). Among metabolically unhealthy patients, those with obesity had similar CT findings as compared with nonobese (P > 0.10 for all). However, both MUN and MUO had unfavorable CAD characteristics as compared with MHN (P ≤ 0.017 for all). A total of 130 events occurred during follow-up (median 26 months). Compared with MHN, MUN (hazard ratio [HR] 1.61 [95% CI 1.02-2.53]) but not MHO (HR 1.06 [0.62-1.82]) or MUO (HR 1.06 [0.66-1.72]) had higher risk for MACE.Conclusions: In patients with stable chest pain, four metabolic phenotypes exhibit distinctly different CAD characteristics and risk for MACE. Individuals who are metabolically unhealthy despite not being obese were at highest risk in our cohort. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
50. Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence.
- Author
-
Perak, Amanda M., Lancki, Nicola, Kuang, Alan, Labarthe, Darwin R., Allen, Norrina B., Shah, Svati H., Lowe, Lynn P., Grobman, William A., Lawrence, Jean M., Lloyd-Jones, Donald M., Lowe, William L., and Scholtens, Denise M.
- Abstract
Importance: Pregnancy may be a key window to optimize cardiovascular health (CVH) for the mother and influence lifelong CVH for her child.Objective: To examine associations between maternal gestational CVH and offspring CVH.Design, Setting, and Participants: This cohort study used data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (examinations: July 2000-April 2006) and HAPO Follow-Up Study (examinations: February 2013-December 2016). The analyses included 2302 mother-child dyads, comprising 48% of HAPO Follow-Up Study participants, in an ancillary CVH study. Participants were from 9 field centers across the United States, Barbados, United Kingdom, China, Thailand, and Canada.Exposures: Maternal gestational CVH at a target of 28 weeks' gestation, based on 5 metrics: body mass index, blood pressure, total cholesterol level, glucose level, and smoking. Each metric was categorized as ideal, intermediate, or poor using pregnancy guidelines. Total CVH was categorized as follows: all ideal metrics, 1 or more intermediate (but 0 poor) metrics, 1 poor metric, or 2 or more poor metrics.Main Outcomes and Measures: Offspring CVH at ages 10 to 14 years, based on 4 metrics: body mass index, blood pressure, total cholesterol level, and glucose level. Total CVH was categorized as for mothers.Results: Among 2302 dyads, the mean (SD) ages were 29.6 (2.7) years for pregnant mothers and 11.3 (1.1) years for children. During pregnancy, the mean (SD) maternal CVH score was 8.6 (1.4) out of 10. Among pregnant mothers, the prevalence of all ideal metrics was 32.8% (95% CI, 30.6%-35.1%), 31.7% (95% CI, 29.4%-34.0%) for 1 or more intermediate metrics, 29.5% (95% CI, 27.2%-31.7%) for 1 poor metric, and 6.0% (95% CI, 3.8%-8.3%) for 2 or more poor metrics. Among children of mothers with all ideal metrics, the prevalence of all ideal metrics was 42.2% (95% CI, 38.4%-46.2%), 36.7% (95% CI, 32.9%-40.7%) for 1 or more intermediate metrics, 18.4% (95% CI, 14.6%-22.4%) for 1 poor metric, and 2.6% (95% CI, 0%-6.6%) for 2 or more poor metrics. Among children of mothers with 2 or more poor metrics, the prevalence of all ideal metrics was 30.7% (95% CI, 22.0%-40.4%), 28.3% (95% CI, 19.7%-38.1%) for 1 or more intermediate metrics, 30.7% (95% CI, 22.0%-40.4%) for 1 poor metric, and 10.2% (95% CI, 1.6%-20.0%) for 2 or more poor metrics. The adjusted relative risks associated with 1 or more intermediate, 1 poor, and 2 or more poor (vs all ideal) metrics, respectively, in mothers during pregnancy were 1.17 (95% CI, 0.96-1.42), 1.66 (95% CI, 1.39-1.99), and 2.02 (95% CI, 1.55-2.64) for offspring to have 1 poor (vs all ideal) metrics, and the relative risks were 2.15 (95% CI, 1.23-3.75), 3.32 (95% CI,1.96-5.62), and 7.82 (95% CI, 4.12-14.85) for offspring to have 2 or more poor (vs all ideal) metrics. Additional adjustment for categorical birth factors (eg, preeclampsia) did not fully explain these significant associations (eg, relative risk for association between 2 or more poor metrics among mothers during pregnancy and 2 or more poor metrics among offspring after adjustment for an extended set of birth factors, 6.23 [95% CI, 3.03-12.82]).Conclusions and Relevance: In this multinational cohort, better maternal CVH at 28 weeks' gestation was significantly associated with better offspring CVH at ages 10 to 14 years. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.